

Recent Progress of Genome Study for Anaplastic Thyroid Cancer

Jieun Lee^{1*}, Jung-Ah Hwang¹, Eun Kyung Lee²

¹Cancer Genomics Branch, Research Institute, National Cancer Center, Goyang 410-769, Korea,

²Center for Thyroid Cancer, National Cancer Center, Goyang 410-769, Korea

Anaplastic thyroid cancer (ATC) belongs to the most malignant and rapidly progressive human thyroid cancers and its prognosis is very poor. Also, it shows high resistance to cancer treatments, so that effective treatment for ATC has not been found to date, and virtually all patients terminate their life rapidly after diagnosis. Although targeted treatment of genetic alterations has emerged as an extremely promising approach to human cancers, such as *BRAF* in metastatic melanoma, it remains unclear that how commonly genomic alterations are influenced in ATC tumorigenesis. In recent years, genome wide approaches have been exploited to find genetic alterations associated with complex diseases, including cancer. Here, we reviewed the comprehensive genetic alterations in ATC and recent approaches in the context of identifying genomic alterations associated with ATC. Since surprisingly few reports have been published on the genome wide study of ATC, this review puts emphasis on the urgent needs of genomic research for the prevention and treatment of ATC.

Keywords: anaplastic thyroid cancer, disease associated alterations, genetic variation

Introduction

Thyroid cancer is the fastest growing cancer worldwide [1]. Especially, in Korea, the average annual incidence rates of thyroid cancer in 2010 was 17.8% recording the highest increasing rate among all cancers (National Cancer Information Center; <http://www.cancer.go.kr/>). Thyroid carcinomas can be sub-classified according to their histological and clinical features such as cellular origins or prognosis [2]. The most common subtype of thyroid cancers are papillary thyroid cancer (PTC; 80% to 85%) and follicular thyroid cancer (FTC; 10% to 25%), which are differentiated tumors derived from follicular epithelial cells. Poorly differentiated thyroid cancer (PDTTC; 5% to 10%) and anaplastic thyroid cancer (ATC; 2% to 3%) are also derived from follicular cells. Parafollicular C cell-derived medullary thyroid cancer (MTC) comprises 2-3% of all thyroid cancers [2, 3]. The overall survival rates for PTC (98%), FTC (92%), and MTC (80%) are high [4], and these types have a more favorable prognosis by multimodality treatment. However, ATC has an almost typically rapid and lethal progression, and the survival rate for ATC is only 13% [4] or 1-17% [2] with a

mean survival of 6 months after diagnosis [5]. Although ATC supposed to be a follicular-cell-derived cancer, and represents a terminal stage in the dedifferentiation of PTC or FTC [6], the molecular mechanisms underlying ATC are not clear. Because ATC is rare disease, it has been difficult to obtain sufficient samples to study the mechanism of the tumorigenesis associated with ATC which should have great impact to survival and treatment of patients [7]. Here, we reviewed the recent progress of the identification of genetic and epigenetic changes in ATC, focusing especially on genomic study. By this effort, we may clarify the further substances of genomic research to conquer the most aggressive type of thyroid carcinomas.

Functional and Frequent Mutations in ATC

To date, a considerable number of genetic mutations have been identified that play roles in the tumorigenesis of ATC, mainly by traditional approaches (Table 1) [8-13]. The most well-known mutation of thyroid cancer is *BRAF*^{V600E}, occurring in approximately 26% of ATCs and 45% of PTCs [8, 14]. The *BRAF*^{V600E} mutant protein is produced by the

Received May 1, 2013; Revised May 16, 2013; Accepted May 21, 2013

*Corresponding author: Tel: +82-31-920-2565, Fax: +82-31-920-2542, E-mail: jieunlee@ncc.re.kr

Copyright © 2013 by the Korea Genome Organization

© It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>).

Table 1. High prevalence of genomic alterations in ATC

Alteration	Gene	Approximate prevalence (%)	Function	Reference
Mutation	<i>BRAF</i>	61/231 (26)	Serine/threonine kinase, regulation of the MAP kinase/erks signaling pathway, invasion, metastasis	[8]
	<i>RAS</i>	37/166 (22)	Regulation of the RAS-RAF-MEK-ERK and the PI3K/AKT1 pathways	[8]
	<i>TP53</i>	12/22 (55)	Tumor suppressor	[8]
	<i>CTNNB1</i>	20/53 (28)	Involved in Wnt signaling and cell-cell adhesion	[8]
	<i>PIK3CA</i>	27/156 (17)	Promoting tumorigenesis and invasiveness	[8]
	<i>Axin</i>	18/22 (82)	Negative regulator of the WNT signaling pathway, induce apoptosis	[8]
	<i>APC</i>	2/22 (9)	Tumor suppressor protein, antagonist of the Wnt signaling pathway	[8]
	<i>PTEN</i>	10/84 (12)	Tumor suppressor, negative regulator of the AKT/PKB signaling pathway; promoting tumorigenesis and invasiveness	[8]
	<i>IDH1</i>	2/18 (11)	Important in the tricarboxylic acid cycle or Krebs cycle	[9]
	<i>ALK</i>	2/8 (25)	A member of the insulin receptor subfamily of receptor tyrosine kinases, probably promoting tumor progression	[10]
Copy number gains	<i>EGFR</i>	19/41 (46)	Member of the protein kinase superfamily, cell surface protein that binds to epidermal growth factor, leads to cell proliferation,	[11]
	<i>PDGFR</i>	11/46 (24)	Members of the platelet-derived growth factor family, organ development, wound healing, and tumor progression	[11]
	<i>PDGFRβ</i>	14/37 (38)	Platelet-derived growth factor receptor	[11]
	<i>VEGFR1</i>	20/44 (46)	Important role in angiogenesis and vasculogenesis	[11]
	<i>VEGFR2</i>	8/46 (17)	VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.	[11]
	<i>KIT</i>	10/46 (22)	Homolog of the proto-oncogene c-kit, type 3 transmembrane receptor for MGF (mast cell growth factor, also known as stem cell factor	[11]
	<i>MET</i>	5/42 (12)	Proto-oncogene, hepatocyte growth factor receptor, tyrosine-kinase activity	[11]
	<i>PIK3Ca</i>	18/47 (38)	Oncogenic and has been implicated in cervical cancers	[11]
	<i>PIK3Cb</i>	16/42 (38)	An isoform of the catalytic subunit of phosphoinositide 3-kinase (PI3K), important in signaling pathways involving receptors on the outer membrane of eukaryotic cells	[11]
	<i>PDK1</i>	8/40 (20)	Regulation of homeostasis of carbohydrate fuels in mammals	[11]
<i>AKT1</i>	9/48 (19)	Critical mediator of growth factor-induced neuronal survival	[11]	
Chromosomal gains	7p (p22-pter)	4/13 (31)	PDGR- α location	[12]
	8q (q22-qter)	3/13 (23)	Myc location	[12]
	9q (q34-qter)	3/13 (23)	ABL1 and VAVZ location	[12]
	3p13-14	4/15 (27)	-	[13]
	11q13	4/15 (27)	Cyclin D1 and FOSL1 location	[13]
Chromosomal loss	5q11-31	5/15 (33)	-	[13]
Rearrangement	RET/PTC	3/20 (15)	RET proto-oncogene encodes a cell membrane tyrosine-kinase receptor protein; RET functions as a multicompetent receptor complex	[11]

ATC, anaplastic thyroid cancer; PI3K, phosphoinositide 3-kinase; VEGF, vascular endothelial growth factor; MGF, mast cell growth factor; PDGR- α , platelet-derived growth factor receptor α .

point mutation of T1799A coding sequence, and as consequence the BRAF kinase shows constitutive activity [15-18]. Its oncogenic and transforming capability has been well studied [19] and interestingly, it is strongly associated with poor prognosis of PTC, including aggressive pathological characteristics, increased recurrence rates, and failure of

treatment [20, 21].

The tumor suppressor gene *p53* is commonly mutated in ATC [8] but uncommon in well-differentiated PTC and FTC. For example, Donghi *et al.* [22] reported that *p53* was mutated in approximately 71% of undifferentiated thyroid cancers (UDTC). Also Fagin *et al.* [23] reported 83%

mutation rate of *p53* in ATCs, and Quiros *et al.* [24] found 88% of *p53* mutation in ATC patients using immunohistochemical analysis.

RAS mutations were detected rarely in PTC, but more prevalently in FTC and ATC [25], as if there are relationship between *RAS* mutations and the aggressiveness of tumor behavior and/or poor prognosis [26, 27]. From three members of *RAS* family (*HRAS*, *KRAS*, and *NRAS*), codon 12/13 of *KRAS* mutation is known to be associated with poor survival for more aggressive subtype of thyroid tumors, including ATC [26]. *RAS* is known as an important regulator of cell growth, differentiation and survival of thyroid cancer [28]. In tumorigenesis, *RAS* may mediate multiple transduction signaling pathways such as Raf-MAPK and phosphatidylinositol 3-kinase (PI3K)/Akt pathways [29].

Mutations of *PIK3CA* are also common in ATC [8]. *PIK3CA* encodes the p110 α catalytic subunit of PI3K and PI3K, in turns, involves in the PTEN/PI3K/AKT pathway, which regulates several cellular processes, including cell cycle progression, adhesion and motility. Especially, this pathway linked to the cell survival, angiogenesis and glucose homeostasis which are important for tumorigenesis [30]. Garcia-Rostan *et al.* [30] showed that the missense mutations of *PIK3CA* are higher in ATC than in others such as well-differentiated thyroid cancer. Additionally, ATC patients who had mutated *PIK3CA* showed also *Ras* or *BRAF* alterations.

Garcia-Rostan *et al.* [31, 32] demonstrated the significant association of mutations in β -catenin and the change of its expression with poor prognosis of ATC. They found that activating mutations of *CTNNB1*, β -catenin encoding gene, often cause the activation of Wnt- β -catenin signaling. In general, as an ubiquitously expressed cytoplasmic protein, β -catenin is a downstream signaling molecule in Wnt pathway, and known to have a crucial role in cell-cell adhesion mediated by E-cadherin. Interestingly, when it is upregulated, the nuclear translocation is occurred so that the transcription of various tumor-promoting genes could be triggered. Axin 1 is a scaffold protein and located in chromosome 16p13.3. It is supposed to be a tumor suppressor and play a role also in the Wnt pathway. Kurihara *et al.* [33] found the mutation of Axin 1 in 81.8% of 22 Japanese ATC samples. Together, the genetic alterations of genes in the Wnt signaling pathway are found frequently with ATC suggesting the important role of Wnt pathway for ATC tumorigenesis.

Although the mutation prevalence is not high, mutations in the gene for isocitrate dehydrogenase 1 (*IDH1*) have been recently identified in ATC [9, 34]. The overall prevalence of mutations of *IDH1* was reported as 11% in 18 ATC samples by Murugan *et al.* [9]. Murugan and Xing [10] reported two

novel point mutations in the anaplastic lymphoma kinase (*ALK*) gene, C3592T and G3602A, with a prevalence of 25% in 8 ATC tumor samples. *ALK*, one of the receptor tyrosine kinases, is a member of insulin receptor subfamily and these transverse point mutations caused the amino acid changes L1198F and G1201E, followed by increase of tyrosine kinase activities. Initially, *ALK* was identified as an oncogenic fusion gene *NPM1-ALK* in anaplastic large-cell non-Hodgkin lymphoma [35]. Further, fusion gene *EML4-ALK* was found in non-small-cell lung cancer [36] and *TMP3/4-ALK* and *RANBP2-ALK* in inflammatory myofibroblastic tumors [37]. They were aberrantly activated and promoted cell proliferation and survival [38, 39].

Although these mutations have been reported to date, it is not clear what of those are the driver mutations of ATC development or if there is any. Also, many other mutations and genes might be associated with ATC tumorigenesis, which may contribute a lot to the diagnosis and treatment of ATC. Therefore, it is a natural consequence that scientists try to adapt genomic approaches to analyze the mechanism of ATC in very recent years.

Chromosomal Aberrations in ATC

Hemmer *et al.* [12] studied DNA copy number changes by comparative genomic hybridization (CGH) in 69 primary thyroid carcinomas including 13 ATC patients. From those 11 ATC cases, showed chromosomal changes (10 gains, 3 deletions, both in 2 cases). Regions of frequent gains were mainly located in 7p22-pter, 8q22-qter, and 9q34-qter regions in 31%, 23% and 23% of ATC cases, respectively. The known proto-oncogenes such as *PDGR- α* , *myc* and *ABL1*, and *VAVZ* are located, in these regions but still no functional evidences were found supporting the association of copy number changes of these regions and the aggressiveness of ATC. Also, Rodrigues *et al.* [40] examined 39 thyroid cancer patients including 7 ATCs. All cases of ATC presented chromosomal imbalances, especially, they found gains at chromosome 20p and 20q, and losses of Xp in 6 cases of ATC, and gains at 3q and 5p in 5 cases ATC. Some important genes included *PI3K*, *BCL6*, and *SST* at 3q; invasion and metastases genes (*MMP9* and *MMP24*), a cell cycle and mitotic checkpoint gene (*STK15*) at 20q. The loss of tumor suppressor gene related 7q31 was detected. The chromosomal instability of ATC revealed as significantly higher than well-differentiated thyroid cancer (WDTC) or PDTC when compared the CGH-detectable abnormalities as reported by couple of studies [12, 40].

Kitamura *et al.* [41] detected allelic losses using 21 ATC patient samples in 1q (40%), 9p (58%), 11p (33%), 11q (33%), 17p (44%), 17q (43%), 19p (36%), and 22q (38%).

Wreesmann *et al.* [13] reported the unique gains at chromosome 3p13-14 and 11q13 (where the cyclin D1 and FOSL1 located) and losses at 5q11-31 in ATC patients.

Liu *et al.* [11] found frequent copy number gains in many receptor tyrosine kinase (*RTK*) genes containing the *EGFR*, *PDGFR α* , *PDGFR β* , *VEGFR1*, *VEGFR2*, *KIT*, *MET*, *PIK3Ca*, *PIK3Cb*, and *PDK1* genes. Many of the genes with copy number gains are known to be proto-oncogenes so that they may play an important role in ATC tumorigenesis by increasing the protein level followed by aberrant activation of the oncogenic pathway. The prevalence of copy number gains was generally higher in ATC than differentiated thyroid cancer [42], also as mentioned in other studies. It is supposed that the copy number variations, which could be occurred by chromosomal amplification or instability,

should be important and involved to the progression and aggressiveness of ATC [43].

Chromosomal alteration could cause the genomic rearrangements and fusion genes. In PTC, rearrangement causing *RET/PTC* fusion gene was observed often, but it rarely occurs in benign follicular thyroid adenoma and follicular variant PTC [44]. Liu *et al.* [11] reported the same *RET/PTC* rearrangement in 3 cases of ATC tissues, but because some ATC tissues contained PTC tissues, they were suspicious to their result. Therefore, if chromosomal rearrangement and fusion genes, including *RET/PTC* fusion, involve to the ATC progression, should be investigated further.

Table 2. Known expression changes in ATC

Gene ontology	Regulation	Gene	Function	Reference
Transcription factors	Upregulation	<i>HSPA8</i>	Acts as a repressor of transcriptional activation	[45]
		<i>CREM</i>	Transcriptional regulator that binds the cAMP response element	[46]
	Downregulation	<i>PAX8</i>	Transcription factor for the thyroid-specific expression	[46, 47]
		<i>CBX7</i>	Transcription regulation	[48]
Signaling pathways	Upregulation	<i>CDKN2A/p16</i>	Kinase	[48]
		<i>TTK</i>	Kinase	[49]
		<i>S100A4</i>	Positive regulation of I-kappaB kinase/NF-kB cascade	[47]
	Downregulation	<i>PBP</i>	Kinase inhibitor	[45]
		<i>FES</i>	Tyrosine-protein kinase	[45]
Mitosis	Upregulation	<i>PRC1</i>	Key regulator of cytokinesis	[49]
		<i>TOP2A</i>	Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands	[49]
		<i>STMND1</i>	Regulation of microtubule polymerization or depolymerization	[45]
Proliferation	Downregulation	<i>TMEM34</i>	Possible tumor suppressor which may play a role in cell growth	[50]
Cell cycle	Upregulation	<i>CDC20</i>	Cell cycle, cell division	[49]
		<i>CDCA8</i>	Cell cycle, cell division	[49]
		<i>CENPF</i>	Cell cycle, cell division	[49]
		<i>PLK1</i>	Cell cycle, cell division	[49]
		<i>NEK2</i>	Cell cycle, cell division	[49]
		<i>CENPA</i>	CENP-A containing nucleosome assembly at centromere	[49]
		<i>CCNB1</i>	Control of the cell cycle at the G2/M	[49]
		<i>UBE2C</i>	Cell cycle, cell division	[47]
		<i>STK5</i>	Cell cycle, cell division	[47]
		<i>B23</i>	Miscellaneous	[45]
Adhesion	Upregulation	<i>DSTN</i>	Actin-depolymerizing protein.	[45]
	Downregulation	<i>CDH1</i>	Cell adhesion	[47]
Metabolism	Upregulation	<i>ATP5A1</i>	ATP synthesis	[45]
		<i>LDH-A</i>	Glycolysis	[45]
		<i>PSMB6</i>	May catalyze basal processing of intracellular antigens.	[45]
		<i>LDH-B</i>	Metabolism	[45]
	Downregulation	<i>TG</i>	Hormone	[45, 47]
		<i>NIS</i>	Mediates iodide uptake in the thyroid gland	[46]
Unknown	Upregulation	<i>HDP-1</i>	Unknown	[45]

ATC, anaplastic thyroid cancer; NF-kB, nuclear factor-kappaB.

Expression Analysis in ATC by Microarray

Although not many investigations for genome wide expression analysis were performed, several studies examined altered expression of genes in ATC cell lines or patient samples using microarray (Table 2) [45-50]. The up- and downregulated genes in ATC identified as players in the regulation of important cellular functions which may influence to the tumorigenesis. Onda *et al.* [45] found 31 over- and 56 under-expressed genes using 11 ATC cell lines compared with normal thyroid gland; then they validated these data with 10 ATC patient samples, among them, *DSTN*, *HSPA8*, *Stathmin*, *LDH-A*, *ATP5A1*, *PSM B6*, *B23*, *HDP-1*, and *LDH-B* were significantly upregulated in primary ATC patient samples. On the other hand, *TG*, *PBP*, and *FES* were downregulated in primary ATC tissues compared with normal thyroid glands. In other study of ATC cell lines, Akaishi *et al.* [50] identified transmembrane protein 34 (*TMEM34*) as specifically downregulated gene.

Although it is not a microarray analysis, Passon *et al.* [46] measured mRNA levels for *CREM*, *PAX8*, and *NIS* in 6 normal thyroid tissues, 22 PTCs, 12 FTCs, and 4 ATCs using quantitative polymerase chain reaction analysis. Compared to normal tissues, *NIS* and *PAX8* mRNA levels were significantly reduced in all types of thyroid cancer, especially in ATCs. Conversely, *CREM* mRNA levels were increased in all types of thyroid cancer including ATC.

To find molecular profile related to poor prognosis of thyroid cancer, Montero-Conde *et al.* [47] examined 7 ATC, 6 PDTC, 24 PTC and 7 FTC tissues by microarray. They comprised 13 dedifferentiated thyroid cancer (ATC and PDTC) vs. 31 WDTC (PTC and FTC) tissues. In this data, they found that 1,031 genes showed more than 2-fold changes of its expression in absolute values. Interestingly, pathways which are known to be associated with tumorigenesis were preferentially altered in ATC and PDTC tissues; the MAP kinase signaling pathway, the transforming growth factor- β signaling pathway, focal adhesion and cell motility, activation of actin polymerization, and cell cycle. *UBE2C*, *S100A4*, and *STK5* were significantly overexpressed in ATC and PDTC than WDTC. *CDH1*, *TG*, and *PAX8* were significantly underexpressed in ATC and PDTC than WDTC, of those the down regulation of *TG* and *PAX8* were also reported by Onda *et al.* [45] and Passon *et al.* [46].

In other study, Pallante *et al.* [48], reported downregulation of *CBX7* expression using microarray analysis in various thyroid carcinoma-derived cell lines. Then, they validated this finding in various thyroid tissue samples. They show that *CBX7* expression decreased with malignancy grade cancer tissues than in normal tissues. Interestingly, in same study, *CBX7* loss of heterozygosity occurred in 36.8%

(7 of 19 cases) of PTCs and in 68.7% (11 of 16 cases) of ATCs. mRNA for *CDKN2A/p16* which is the molecular target of *CBX7* and known to be a tumor suppressor, was also highly expressed.

As direct study of patient samples, Salvatore *et al.* [49] did a microarray analysis using 5 ATC compared with 10 PTC and 4 normal thyroid tissue and validated their data with further 22 ATC, 39 PTC and 19 normal thyroid samples. 914 genes distinguished ATC from normal tissue: and only 114 genes were found to discriminate normal thyroid from both PTC and ATC. Especially, 54 genes were upregulated in ATC and they are largely involved in cell cycle progression or chromosome instability. Among them, *TOP2A*, *CDC20*, *CENPA*, *NEK2*, *PRC1*, *CCNB1*, *CDCA8*, *TTK*, *CENPF*, and *PLK1* expression was ATC-specifically up-regulated.

Taken together, the previous studies of genomic expression analysis suggested some of interesting genes and molecular changes using microarray, they could not find clearly the major driver genes or pathways for ATC tumorigenesis. This may be due to the hardness of sample collection or ATC itself could have a very complex heterogeneity. But the technical limitation of microarray itself may contribute also largely. The recently applicable next generation sequencing technology could help to solve this issue so that the molecular contribution of gene expression changes for ATC could be resolved.

Epigenetic Alterations in ATC

Since the epigenetic changes of tumor-associated genes are known to play an important role and have physiological function in the development of various human cancers and its progression [51, 52], they may also influence to the tumorigenesis of the most malignant form of thyroid cancer, ATC. In PTC cells, genome-wide hypermethylation was found by a recent study using DNA methylation microarray which is revealed to be driven by *BRAF*^{V600E} signaling [53]. Other couple of papers focused more on the change of methylation pattern in ATC. Schagdarsurengin *et al.* [54] analyzed the methylation pattern of 17 gene promoters in ATC, included those involved in DNA damage avoidance and repair (*MGMT*, *GSTP1*), apoptosis (*DAPK*, *UCHL1*), cell cycle control (*p16*, *RB*), tumor invasion and metastasis (*TIMP3*, *CD26*), hormone response (*RAR β* , *ER α* , *ER β*), signal transduction (*PTEN*, *RASSF1A*), regulation of thyrocyte function and growth (*TSHR*), and other tumor-associated genes (*DLC1*, *SLC5A8*). Among these genes, they found that *TSHR*, *MGMT*, *UCHL1*, *p16*, and *DAPK* were frequently methylated in ATC.

PTEN, as a well-established tumor suppressor, is involved in the PI3K/AKT pathway. Hou *et al.* [55] found that *PTEN*

methylation is necessary to progress the malignancy from benign thyroid adenoma to FTC and aggressive ATC. The methylation of a gene is usually associated with its silencing and the increased methylation of *PTEN* in ATC is in concordance with decreased or even lack of *PTEN* expression in previous reports [56, 57]. They also found that *PTEN* methylation in thyroid tumors was closely associated with the activating genetic alterations in the PI3K/Akt pathway, including mutations in *Ras*, *PIK3CA*, *PTEN* gene and *PIK3CA* amplification [55].

Four microRNAs (miRs) (-30d, -125b, -26a, and 30a-5p) were reported by Visone *et al.* [58] as decreased in ATC compared with normal thyroid tissue. From these, miR-26a and -125b may be targeting *HMGA1* and *HMGA2* which are known to be involved in thyroid cell transformation [59]. In other report by Mitomo *et al.* [60], found the upregulation of miRs-21, -146b, -221, and -222 and downregulation of -26a, -138, -219, and -345 in thyroid cancer. From these, miR-21 targets E2F (involved in cell cycle and apoptosis) and inhibits *PTEN*. Interestingly, miR-138 which was found to be downregulated in both study of Visone's and Mitomo's group [58, 60], targets *hTERT* which is also found to be reduced. Takakura *et al.* [61] identified ATC specifically deregulated miRNAs in ATC cell line. They found that overexpression of miR-17-92 cluster of 7 miRNAs (miR-17-3p, -17-5p, -18a, -19a, -19b, -20a, and -92-1), which has a crucial role in cell growth and survival. Additionally, miR-17-3p and -17-5p 5p were overexpressed in 3 out of the 6 ATC patient samples.

Conclusion

Although ATC is known to be one of the most aggressive tumor types, there has been little progress in the diagnosis and treatment, largely due to the shortage of genetic information associated with the molecular mechanism of ATC tumorigenesis. In this review, we discussed genetic alterations, structural variations, and epigenetic changes of ATC performed by many scientists to date. As shown, only limited information is available, and few studies were performed using genome-based approaches. Generally, the quantities and qualities of samples for genomic study are very high, so that it is not easy to fulfill the requirements. Therefore, collecting a sufficient number of samples for ATC matching these criteria is a kind of challenge for many scientists. However, current next-generation sequencing techniques require smaller amounts of samples and are applicable for less-qualified samples but provide more accurate results for researchers to evaluate diverse genetic alterations.

Recently, the technical advances of genome study devel-

oped explosively so that it could provide more comprehensive information on cancer genomics, especially for gene expression, sequence variations, copy number changes, and epigenetic changes [62]. Using such technology such as next generation sequencing and big data, rapid progress has been realized in many parts of cancer molecular biology, which in turn contributes to the development of early diagnosis tools and/or targeted molecular therapies. Thus, less-detailed cancer types have been intensively targeted by current genomic studies. For example, many studies have analyzed the genomic alterations associated with lung cancer and reported detailed molecular events that could be used directly in the clinic, such as selection of the most effective drug for each patient. For thyroid cancer, The Cancer Genome Atlas (TCGA) has deposited the analysis results of 500 thyroid cancer genomes in their public website, which may be published very soon. These analyses will provide a more detailed, multidimensional genomic characterization of thyroid cancer genomes. However, most of the 500 thyroid cancer genomes in TCGA were only from PTC patients, and none was from an ATC patient.

It is clear that genomic study of ATC is urgently needed so that the molecular mechanisms of ATC and the genetic and epigenetic changes in ATC could be more precisely understood. Studies on ATC-associated genetic alterations, such as mutations and aberrant structural and epigenetic changes, based on genomic approaches should help to elucidate the molecular consequences of the activation of oncogenes and the loss of tumor suppressors to improve our understanding of tumor biology in ATC. Especially, using recently developed NGS technology, we will get a deep understanding of ATC-specific molecular mechanisms for successful diagnosis and treatment of this aggressive cancer and further facilitate the search for prognostic and predictive markers and new therapeutic targets for personalized medicine.

Acknowledgments

This study was supported by Intramural Research Grants of the National Cancer Center, Korea (NCC 1210340).

References

1. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, *et al.* International patterns and trends in thyroid cancer incidence, 1973-2002. *Cancer Causes Control* 2009;20:525-531.
2. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. *Nat Rev Cancer* 2006;6:292-306.
3. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. *Nat Rev Cancer* 2013;13:184-199.

4. Sherman SI. Thyroid carcinoma. *Lancet* 2003;361:501-511.
5. Nix PA, Nicolaidis A, Coatesworth AP. Thyroid cancer review 3: management of medullary and undifferentiated thyroid cancer. *Int J Clin Pract* 2006;60:80-84.
6. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. *Thyroid* 1998;8:715-726.
7. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. *Ann Oncol* 2000;11:1083-1089.
8. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. *Endocr Relat Cancer* 2009;16:17-44.
9. Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (*IDH1*) mutations in thyroid cancer. *Biochem Biophys Res Commun* 2010;393:555-559.
10. Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the *ALK* gene. *Cancer Res* 2011;71:4403-4411.
11. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. *J Clin Endocrinol Metab* 2008;93:3106-3116.
12. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H. DNA copy number changes in thyroid carcinoma. *Am J Pathol* 1999;154:1539-1547.
13. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, et al. Genome-wide appraisal of thyroid cancer progression. *Am J Pathol* 2002;161:1549-1556.
14. Xing M. *BRAF* mutation in thyroid cancer. *Endocr Relat Cancer* 2005;12:245-262.
15. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, et al. *BRAF* mutations in papillary carcinomas of the thyroid. *Oncogene* 2003;22:6455-6457.
16. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of *BRAF* mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. *Cancer Res* 2003;63:1454-1457.
17. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. *BRAF* mutations and *RET/PTC* rearrangements are alternative events in the etiopathogenesis of PTC. *Oncogene* 2003;22:4578-4580.
18. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of *BRAF* gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. *Cancer Res* 2003;63:4561-4567.
19. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the *BRAF* gene in human cancer. *Nature* 2002;417:949-954.
20. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. *BRAF* mutation predicts a poorer clinical prognosis for papillary thyroid cancer. *J Clin Endocrinol Metab* 2005;90:6373-6379.
21. Xing M. Prognostic utility of *BRAF* mutation in papillary thyroid cancer. *Mol Cell Endocrinol* 2010;321:86-93.
22. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA. Gene *p53* mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. *J Clin Invest* 1993;91:1753-1760.
23. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the *p53* gene in poorly differentiated human thyroid carcinomas. *J Clin Invest* 1993;91:179-184.
24. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to *BRAF* and *p53* mutations. *Cancer* 2005;103:2261-2268.
25. Capella G, Matias-Guiu X, Ampudia X, de Leiva A, Perucho M, Prat J. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues. *Diagn Mol Pathol* 1996;5:45-52.
26. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. *J Clin Oncol* 2003;21:3226-3235.
27. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. *Expert Rev Mol Diagn* 2008;8:83-95.
28. Crespo P, Leon J. Ras proteins in the control of the cell cycle and cell differentiation. *Cell Mol Life Sci* 2000;57:1613-1636.
29. Luo J, Manning BD, Cantley LC. Targeting the *PI3K-Akt* pathway in human cancer: rationale and promise. *Cancer Cell* 2003;4:257-262.
30. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, et al. Mutation of the *PIK3CA* gene in anaplastic thyroid cancer. *Cancer Res* 2005;65:10199-10207.
31. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and *CTNNB1* exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. *Am J Pathol* 2001;158:987-996.
32. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. *Cancer Res* 1999;59:1811-1815.
33. Kurihara T, Ikeda S, Ishizaki Y, Fujimori M, Tokumoto N, Hirata Y, et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. *Thyroid* 2004;14:1020-1029.
34. Hemerly JP, Bastos AU, Cerutti JM. Identification of several novel non-p.R132 *IDH1* variants in thyroid carcinomas. *Eur J Endocrinol* 2010;163:747-755.
35. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, *ALK*, to a nuclear protein gene, *NPM*, in non-Hodgkin's lymphoma. *Science* 1994;263:1281-1284.
36. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming *EML4-ALK* fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561-566.
37. Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, Zhou M, et

- al. Fusion of ALK to the Ran-binding protein 2 (*RANBP2*) gene in inflammatory myofibroblastic tumor. *Genes Chromosomes Cancer* 2003;37:98-105.
38. Lange K, Uckert W, Blankenstein T, Nadrowitz R, Bittner C, Renauld JC, *et al.* Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. *Oncogene* 2003;22:517-527.
 39. Wellmann A, Doseeva V, Butscher W, Raffeld M, Fukushima P, Stetler-Stevenson M, *et al.* The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. *FASEB J* 1997;11:965-972.
 40. Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J. Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. *Br J Cancer* 2004;90:492-496.
 41. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. *Genes Chromosomes Cancer* 2000;27:244-251.
 42. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D. *In vitro* reconstruction of tumour initiation in a human epithelium. *Oncogene* 1994;9:281-290.
 43. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, *et al.* Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. *Clin Cancer Res* 2007;13:1161-1170.
 44. Marotta V, Guerra A, Sapio MR, Vitale M. *RET/PTC* rearrangement in benign and malignant thyroid diseases: a clinical standpoint. *Eur J Endocrinol* 2011;165:499-507.
 45. Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi J, Asaka S, *et al.* Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. *Endocr Relat Cancer* 2004;11:843-854.
 46. Passon N, Puppini C, Lavarone E, Bregant E, Franzoni A, Hershman JM, *et al.* Cyclic AMP-response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells. *Thyroid* 2012;22:487-493.
 47. Montero-Conde C, Martin-Campos JM, Lerma E, Gimenez G, Martinez-Guitarte JL, Combalia N, *et al.* Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. *Oncogene* 2008;27:1554-1561.
 48. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, *et al.* Loss of the *CBX7* gene expression correlates with a highly malignant phenotype in thyroid cancer. *Cancer Res* 2008;68:6770-6778.
 49. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, *et al.* A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. *Cancer Res* 2007;67:10148-10158.
 50. Akaishi J, Onda M, Okamoto J, Miyamoto S, Nagahama M, Ito K, *et al.* Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer. *J Cancer Res Clin Oncol* 2007;133:213-218.
 51. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. *N Engl J Med* 2003;349:2042-2054.
 52. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet* 2002;3:415-428.
 53. Hou P, Liu D, Xing M. Genome-wide alterations in gene methylation by the *BRAF* V600E mutation in papillary thyroid cancer cells. *Endocr Relat Cancer* 2011;18:687-697.
 54. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R. CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. *Thyroid* 2006;16:633-642.
 55. Hou P, Ji M, Xing M. Association of *PTEN* gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. *Cancer* 2008;113:2440-2447.
 56. Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chiappetta G, *et al.* *PTEN* expression is reduced in a subset of sporadic thyroid carcinomas: evidence that *PTEN*-growth suppressing activity in thyroid cancer cells mediated by p27kip1. *Oncogene* 2000;19:3146-3155.
 57. Frisk T, Foukakis T, Dwight T, Lundberg J, Hoog A, Wallin G, *et al.* Silencing of the *PTEN* tumor-suppressor gene in anaplastic thyroid cancer. *Genes Chromosomes Cancer* 2002;35:74-80.
 58. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, *et al.* Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. *Oncogene* 2007;26:7590-7595.
 59. Berlingieri MT, Pierantoni GM, Giacotti V, Santoro M, Fusco A. Thyroid cell transformation requires the expression of the *HMG1* proteins. *Oncogene* 2002;21:2971-2980.
 60. Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibasaki M, Yashima-Abo A, *et al.* Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. *Cancer Sci* 2008;99:280-286.
 61. Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch TI, *et al.* Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. *Cancer Sci* 2008;99:1147-1154.
 62. Kwon SM, Cho H, Choi JH, Jee BA, Jo Y, Woo HG. Perspectives of integrative cancer genomics in next generation sequencing era. *Genomics Inform* 2012;10:69-73.